Alfa-epoietin and Anaemia in Gynaecological Cancer

Barbara Di Cocco, Nello Salesi, Alessandra Fabi, Chiara Nardoni, Gianluigi Ferretti, Giandominik Bossone, Mariangela Ciccarese, Antonella Savarese, Aldo Vecchione, Francesco Cognetti

Research output: Contribution to journalArticle

Abstract

The incidence and severity of anaemia in gynaecological cancer patients depends on several factors including age, histology and tumor stage, site of neoplasm and treatment. At present, two principal opinions are available for the management of chronic anaemia in cancer patients: blood transfusions and treatment with recombinant human Erythropoietin (rHuEPO). Clinical studies showed that rHuEPO can ameliorate chronic and chemotherapy-induced anaemia and reduce transfusions in patients with various malignant diseases. In this review we discuss the role of alfa-epoetin in the management of gynaecological and breast cancers.

Original languageEnglish
Pages (from-to)1287-1292
Number of pages6
JournalAnticancer Research
Volume24
Issue number2 C
Publication statusPublished - Mar 2004

    Fingerprint

Keywords

  • Alfa-erythropoietin
  • Anaemia
  • Gynaecological cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Di Cocco, B., Salesi, N., Fabi, A., Nardoni, C., Ferretti, G., Bossone, G., Ciccarese, M., Savarese, A., Vecchione, A., & Cognetti, F. (2004). Alfa-epoietin and Anaemia in Gynaecological Cancer. Anticancer Research, 24(2 C), 1287-1292.